Form 8-K - Current report:
SEC Accession No. 0000950170-22-011646
Filing Date
2022-06-15
Accepted
2022-06-14 19:34:00
Documents
12
Period of Report
2022-06-14
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K janx-20220614.htm   iXBRL 8-K 76705
  Complete submission text file 0000950170-22-011646.txt   203050

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT janx-20220614.xsd EX-101.SCH 2461
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT janx-20220614_lab.xml EX-101.LAB 14743
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT janx-20220614_pre.xml EX-101.PRE 11865
6 EXTRACTED XBRL INSTANCE DOCUMENT janx-20220614_htm.xml XML 5110
Mailing Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037
Business Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037 858-750-4700
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 221016297
SIC: 2834 Pharmaceutical Preparations